T cell response to hepatitis B virus antigen

The T cell immune response to hepatitis B virus antigens encompasses the activity of CD4+ and CD8+ T lymphocytes that recognize and respond to HBV-derived antigens presented by infected hepatocytes or antigen-presenting cells. CD8+ T cells (cytotoxic T lymphocytes) can kill infected hepatocytes directly or secrete antiviral cytokines to suppress HBV replication, while CD4+ T cells provide help for antibody production and cytotoxic responses. Strength and breadth of T cell responses are major determinants of HBV clearance versus chronicity. Chronic exposure to viral antigen, as in persistent HBV infection, commonly results in T cell dysfunction or exhaustion, characterized by upregulation of inhibitory receptors (e.g., PD-1), diminished cytokine production, and impaired cytotoxicity[1][2][3][4]. Genetic factors, such as HLA alleles, modulate the diversity and effectiveness of T cell responses to HBV antigens[1]. This biological process is not a molecular target itself and thus is not suitable for inclusion in a structured therapeutic target database as a receptor, enzyme, or otherwise discrete protein[1][2][3][4].

Other names

Adaptive T cell response to HBV antigenHBV-specific T cell responseT cell-mediated immunity to hepatitis B